Comment Re:This is exciting news (Score 1) 208
until you factor in the inevitable greed variable from the Pharmaceutical Cartel.
No surprise here, especially considering that this one is really a study by Cortexyme, Inc that is developing treatments for Alzheimer's and other degenerative disorders.
The list of authors and affiliations should be enough to give anyone pause: of the 13 authors the corresponding one (i.e., the one who got the study published) is Stephen S. Dominy from Cortexyme, Hatice Hasturk is affiliated with The Forsyth Institute "reinventing oral and overall health through pioneering biomedical research and transformational healthcare practices", and most of the others come from departments of oral immunology, dental medicine, periodontology, etc.
This alone should be enough to make anyone very suspicious but, in the event it isn't, the introduction clearly states:
"Infectious agents have been found in the brain and postulated to be involved with AD, but robust evidence of causation has not been established
[...]
P. gingivalis lipopolysaccharide has been detected in human AD brains, promoting the hypothesis that P. gingivalis infection of the brain plays a role in AD pathogenesis.
[...]
We developed and tested potent, selective, brain-penetrant, small-molecule gingipain inhibitors in vivo. Our results indicate that small-molecule inhibition of gingipains has the potential to be disease modifying in AD."
So, according to the author(s) there is "no robust evidence" that P. gingivalis is really the cause of AD, but Cortexyme will be happy to sell you something that may (or may not) work. In other words, the article is just another press release in disguise.
RT.